These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26702991)

  • 1. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
    Gaudet M; Vigneault É; Foster W; Meyer F; Martin AG
    Radiother Oncol; 2016 Jan; 118(1):141-7. PubMed ID: 26702991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
    Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
    Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
    Evers J; Kupper N; Kessing D; Davits R; Engelen A; Poortmans P; Mols F
    Urology; 2010 Nov; 76(5):1150-6. PubMed ID: 20869105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

  • 9. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
    Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
    Bittner N; Merrick GS; Butler WM; Galbreath RW; Anderson RL; Adamovich E; Wallner KE
    Brachytherapy; 2012; 11(3):219-23. PubMed ID: 21820364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
    McPartlin AJ; Glicksman R; Pintilie M; Tsuji D; Mok G; Bayley A; Chung P; Bristow RG; Gospodarowicz MK; Catton CN; Milosevic M; Warde PR
    Cancer; 2016 Aug; 122(16):2595-603. PubMed ID: 27219522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
    Usami M; Akaza H; Arai Y; Hirano Y; Kagawa S; Kanetake H; Naito S; Sumiyoshi Y; Takimoto Y; Terai A; Yoshida H; Ohashi Y
    Prostate Cancer Prostatic Dis; 2007; 10(2):194-201. PubMed ID: 17199134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H; Hinotsu S; Usami M; Arai Y; Kanetake H; Naito S; Hirao Y;
    Cancer; 2009 Aug; 115(15):3437-45. PubMed ID: 19536889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
    Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
    Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.